{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:59:39Z","timestamp":1762001979918,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ymgmr.2022.100933","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T19:03:58Z","timestamp":1667934238000},"page":"100933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening"],"prefix":"10.1016","volume":"33","author":[{"given":"Hela","family":"Hajji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apolline","family":"Imbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Spraul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmia","family":"Taibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalila","family":"Habes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Bouchereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Sissaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Lacaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Debray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"de Lonlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2022.100933_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-319-55780-9_2","article-title":"Biochemical and clinical aspects of hereditary tyrosinemia type 1","volume":"959","author":"Morrow","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0010","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.1840200513","article-title":"Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment","volume":"20","author":"van Spronsen","year":"1994","journal-title":"Hepatol. Baltim. Md."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(92)92685-9","article-title":"Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase","volume":"340","author":"Lindstedt","year":"1992","journal-title":"Lancet Lond. Engl."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgmr.2022.100933_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF03335416","article-title":"Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem","volume":"12","author":"van Spronsen","year":"1989","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.ymgmr.2022.100933_bb0025","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1007\/s10545-012-9569-8","article-title":"Maternal and fetal tyrosinemia type I","volume":"33","author":"Garcia Segarra","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2012.05.022","article-title":"Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Qu\u00e9bec","volume":"107","author":"Larochelle","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13023-014-0107-7","article-title":"Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice","volume":"9","author":"Mayorandan","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0040","first-page":"362","article-title":"Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy, BMC res","volume":"6","author":"Mohamed","year":"2013","journal-title":"Notes."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10545-006-0203-5","article-title":"Cardiomyopathy in tyrosinaemia type I is common but usually benign","volume":"29","author":"Arora","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-8-8","article-title":"Recommendations for the management of tyrosinaemia type 1","volume":"8","author":"de Laet","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0055","article-title":"Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations","volume":"19","author":"Chinsky","year":"2017","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/TACG.S113310","article-title":"Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)","volume":"10","author":"Das","year":"2017","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(21)00092-9","article-title":"Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study","volume":"9","author":"Spiekerkoetter","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1089-3261(05)70142-2","article-title":"Nontransplant treatment of tyrosinemia","volume":"4","author":"Holme","year":"2000","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-319-55780-9_19","article-title":"Remaining challenges in the treatment of Tyrosinemia from the Clinician\u2019s viewpoint","volume":"959","author":"Mitchell","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-3476(05)80501-3","article-title":"Biphasic reduction and concanavalin a binding properties of serum alpha-fetoprotein in preterm and term infants","volume":"118","author":"Lahdenne","year":"1991","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0085","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1542\/peds.2014-1913","article-title":"Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP","volume":"135","author":"van Ginkel","year":"2015","journal-title":"Pediatrics."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0090","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1469-8749.2011.04048.x","article-title":"Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1","volume":"53","author":"De Laet","year":"2011","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-016-0472-5","article-title":"Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls","volume":"11","author":"van Ginkel","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-319-55780-9_10","article-title":"Neurological and neuropsychological problems in Tyrosinemia type I patients","volume":"959","author":"van Ginkel","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13023-019-1259-2","article-title":"Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients","volume":"14","author":"van Vliet","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0110","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s11011-017-0071-8","article-title":"Abnormal social behavior in mice with tyrosinemia type I is associated with an increase of myelin in the cerebral cortex","volume":"32","author":"Moore","year":"2017","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0115","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10545-016-9949-6","article-title":"Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice","volume":"39","author":"Hillgartner","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-021-01879-1","article-title":"Treatment adherence in tyrosinemia type 1 patients","volume":"16","author":"Gonz\u00e1lez-Lamu\u00f1o","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10545-011-9429-y","article-title":"French-Belgian study group for HT-1, heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines","volume":"35","author":"Schiff","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100933_bb0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-319-55780-9_13","article-title":"Newborn screening for hereditary Tyrosinemia type I in Qu\u00e9bec: update","volume":"959","author":"Gigu\u00e8re","year":"2017","journal-title":"Adv. Exp. Med. Biol."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:54:16Z","timestamp":1762001656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"alternative-id":["S2214426922000933"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100933","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100933"}}